[DOI] [PubMed] [Google Scholar] 4.Jain S.K., Velusamy T., Croad J.L., Rains J.L., Bull R
CD14+CD33+ myeloid cell-CCL11-eosinophil signature in ulcerative colitis
The near-balanced peptide was shown to be ~2-fold less potent at GLP-1R and ~10 fold less potent at GCGR than native ligands in cAMP synthesis (75)
GLP-1RA also reduced the risk of cardiovascular death by 13% (P = 0.016), nonfatal stroke by 16% (P = 0.007), hospitalization for heart failure by 10% (P = 0.023), all-cause mortality by 12% (P = 0.012), and the broad composite kidney outcome by 17% (P = 0.012), which was driven by a reduction in macroalbuminuria only (HR = 0.74, 0.670.82, P 18 years old) patients with T2DM
These two peptides have generated tremendous interest within athletic, biohacking, and regenerative health communities over the past decade
These results suggest that the dimer form could be a more effective GSTP1 inhibitor, possibly due to stronger binding interactions within the GSTP1 active site